Breakthroughs in Leveraging Biomarkers for Oncology

NEW YORK, Oct. 18, 2017 /PRNewswire/ -- Predictive biomarkers are used to provide the best treatment indication with the greater probability of response to a certain specific chemotherapeutic agent, also considering treatment-related side effects. Prognostic biomarkers are used to identify patients with different clinical outcomes associated with somatic mutations, alterations in DNA methylation, germline polymorphisms, serum cytokine levels, expression of micro-RNA (miRNA) as well as circulating tumor cells (CTCs) in blood. Therefore, the precise identification of highly specific and sensitive biomarkers corresponding to certain clinical outcomes or antitumor effects constitutes one of the most crucial tasks in cancer research and treatment.



Read the full report: https://www.reportlinker.com/p05149324



This research service depicts how biomarkers research has remarkably progressed in oncology and accelerates novel therapeutics discovery and development. In fact, recent biomarker research has outstandingly progressed and assisted early drug discovery and development by providing novel molecular-targeting agents in the field of oncology.

Read the full report: https://www.reportlinker.com/p05149324

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com  


__________________________
Contact Clare: [email protected]  
US: (339)-368-6001
Intl: +1 339-368-6001 

SOURCE Reportlinker